{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:11:15Z","timestamp":1792069875710,"version":"4.4.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Recurrent vulvovaginal candidiasis (RVVC) is defined as 3 or more acute symptomatic episodes in a year and affects nearly 138 million women globally. Oteseconazole selectively inhibits fungal cytochrome P51 and has potent activity against\n                      <jats:italic toggle=\"yes\">Candida albicans<\/jats:italic>\n                      and resistant species, including\n                      <jats:italic toggle=\"yes\">C. glabrata<\/jats:italic>\n                      and fluconazole-resistant strains. Over 90% of women randomized to receive oteseconazole in two recently completed global Phase 3 clinical trials (VIOLET trials) did not experience a RVVC episode during these 48-week clinical studies. This observational study was designed to extend these initial findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>A total of 70 eligible women previously randomized to receive oteseconazole were enrolled into an extension study and were followed an additional 48 weeks and monitored for recurrent infections. No additional investigational treatment was administered during the observational period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 70 eligible study participants who received oteseconazole, 85% completed the extension study, and 1\/70 (1.4%) experienced a culture-verified recurrent infection during the observational period, weeks 48 to 96. Of the participants initially randomized to receive placebo, 76% completed the study and 3\/17 (17.6%) experienced a recurrent infection during the extension study. The proportion of participants who prematurely discontinued the study was lower in the oteseconazole-treated group (16%) compared with the placebo group (29%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>During the 48-week extension study, 1.4% of previously randomized subjects experienced a culture-positive recurrence of symptomatic vulvovaginal candidiasis, demonstrating a continued long-term protective effect of oteseconazole.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15409996251394811","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T08:03:18Z","timestamp":1762588998000},"page":"334-339","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Sustained Efficacy of Oteseconazole in Women with Recurrent Vulvovaginal Candidiasis"],"prefix":"10.1177","volume":"35","author":[{"given":"Samuel N.","family":"Lederman","sequence":"first","affiliation":[{"name":"Altus Clinical Research, Lake Worth, Florida, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sobel","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Jefferson Vulvovaginal Health Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack D.","family":"Sobel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey B.","family":"Curelop","sequence":"additional","affiliation":[{"name":"Mycovia Pharmaceuticals Inc, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Brand","sequence":"additional","affiliation":[{"name":"Mycovia Pharmaceuticals Inc, Durham, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.06.067"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30103-8"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e318273e8cf"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2017.08.010"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000239103.67452.1a"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy776"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof6030113"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.5.2155-2162.2005"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033114"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7004a1"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_3_3_13_2","unstructured":"Diflucan prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/019949s051lbl.pdf"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003604"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/aog.0b013e31827307b2"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000496"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.05.068"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100055"},{"key":"e_1_3_3_19_2","unstructured":"VIVJOA prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215888s000ibl.pdf"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15409996251394811","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15409996251394811","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15409996251394811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:51:00Z","timestamp":1787125860000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15409996251394811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,9]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.1177\/15409996251394811"],"URL":"https:\/\/doi.org\/10.1177\/15409996251394811","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,9]]}}}